Why is vincristine capped at 2 mg per dose?

The 2 mg dose cap (vincristine cap) is a safety convention based on clinical experience; doses above 2 mg showed increased severe neuropathy without proportional efficacy gain in adult patients. The cap is controversial and not applied in all pediatric protocols where full BSA-based dosing may improve outcomes.

What are signs of vincristine-induced autonomic neuropathy?

Constipation (most common), ileus, orthostatic hypotension, bladder dysfunction, and jaw pain. Prophylactic stool softeners should be given with every vincristine dose. Severe ileus requires treatment interruption and bowel regimen intensification.

Vincristine Neuropathy Cumulative Limit

Monitor cumulative vincristine dose relative to peripheral neuropathy risk, with dose capping at 2 mg per dose to prevent severe CIPN and autonomic neuropathy.

⚕ Clinical Disclaimer: These calculators are for educational and reference purposes only. Always verify results with qualified clinical judgment and current clinical guidelines. Do not use as a sole basis for medical decisions.

How to Use

Enter the values for the scenario you are assessing. Monitor cumulative vincristine dose relative to peripheral neuropathy risk, with dose capping at 2 mg per dose to prevent severe CIPN and autonomic neuropathy. Use the vincristine limit result to inform your calculation.

Related Calculators

Paclitaxel Neuropathy

Medical Long-tail

BSA DuBois